Article

Sport-tinted lens filters blue light, sharpens vision

Rochester, NY–Bausch & Lomb plans to launch its Nike Maxsight (polymacon) sport-tinted contact lens later this summer now that the FDA has cleared the lens for market distribution.

The soft contact lens corrects refractive myopia and hyperopia while filtering specific wavelengths of light to enhance sports settings. The lensreduces distracting sun glare during outdoor activities, making a ball or other objects more visible than with the naked eye, Bausch & Lomb claims. The company said the patented Light Architecture optics filter most of the blue light and manipulate the remaining colors of the spectrum to enhance visibility of the ball. Wearers will not have to contend with the difficulties associated with spectacles–fogged or scratched lenses, sweating, or a nosepiece or frame that limits vision.

Bausch & Lomb said it will manufacture the lens and market it to eye-care professionals, while Nike–which had solicited Bausch & Lomb 3 years ago as a partner in the lens–will handle consumer marketing.

Although the lens is indicated for daily wear, the company recommends wearing it for shorter periods, and replacing them after 30 days.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.